SCHEMBL15532609

SCHEMBL15532609

CS(=O)(=O)OCCOCCOCCOCCOCCOCCOC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.40
TSHR P16473 2/20 0.40
ALDH1A1 P00352 7/20 0.36
LMNA P02545 6/20 0.36
KDM4E B2RXH2 2/20 0.36
MMP9 P14780 2/20 0.36
USP2 O75604 1/20 0.36
ALOX15 P16050 1/20 0.36
MEN1 O00255 2/20 0.36
HTT P42858 2/20 0.36
KMT2A Q03164 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
EPHX2 P34913 8/20 0.34
MAPK1 P28482 1/20 0.33
SCN9A Q15858 1/20 0.33
MMP2 P08253 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15532287 1.00 SMN1; SMN2 (0.40) SMN1; SMN2TSHRALDH1A1LMNAKDM4E
SCHEMBL21996771 1.00 SMN1; SMN2 (0.40) SMN1; SMN2TSHRALDH1A1LMNAKDM4E
SCHEMBL15532690 1.00 SMN1; SMN2 (0.40) SMN1; SMN2TSHRALDH1A1LMNAKDM4E
SCHEMBL15532087 0.80 MEN1 (0.43) TSHRALDH1A1LMNAKDM4EMMP9
SCHEMBL21998197 0.79 SMN1; SMN2 (0.36) SMN1; SMN2TSHRALDH1A1LMNAKDM4E
SCHEMBL16682526 0.77 EPHX2 (0.44) SMN1; SMN2TSHRALDH1A1LMNAMEN1
SCHEMBL25753188 0.77 EPHX2 (0.45) SMN1; SMN2TSHRALDH1A1LMNAMEN1
SCHEMBL15533591 0.77 EPHX2 (0.45) SMN1; SMN2TSHRALDH1A1LMNAMEN1
SCHEMBL2084363 0.74 EPHX2 (0.43) SMN1; SMN2TSHRALDH1A1LMNAKDM4E
SCHEMBL12687776 0.74 ALDH1A1 (0.35) SMN1; SMN2TSHRALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same YALE UNIVERSITY 2016-01-28 US disclosed
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same YALE UNIVERSITY 2016-01-28 US disclosed
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same YALE UNIVERSITY 2016-01-28 US disclosed
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY 2015-04-30 US disclosed
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY 2015-04-30 US disclosed
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY 2015-04-30 US disclosed
EP-2846784-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME Yale University (US) 2015-03-18 EP disclosed
WO-2013170147-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY (US) 2013-11-14 WO disclosed
WO-2013170147-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME YALE UNIVERSITY (US) 2013-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119435-A1 COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME PSMG3, ERAP1, SMURF2 SMN1; SMN2 1443/4885TSHR 4349/4885ALDH1A1 1405/4885
US-20160022642-A1 Compounds Useful for Promoting Protein Degradation and Methods Using Same AR, SHBG, PSMG3 SMN1; SMN2 2606/4885TSHR 2584/4885ALDH1A1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.